

Winnie Yeo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2808532/publications.pdf>

Version: 2024-02-01

274
papers

18,422
citations

26630

56
h-index

13771

129
g-index

289
all docs

289
docs citations

289
times ranked

17898
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of high adherence to vegetables and fruits dietary pattern with quality of life among Chinese women with early-stage breast cancer. <i>Quality of Life Research</i> , 2022, 31, 1371-1384.	3.1	5
2	Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 649-658.	2.5	1
3	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	1.6	9
4	Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. <i>Acupuncture in Medicine</i> , 2021, 39, 41-52.	1.0	3
5	Longitudinal change of quality of life in the first five years of survival among disease-free Chinese breast cancer survivors. <i>Quality of Life Research</i> , 2021, 30, 1583-1594.	3.1	5
6	Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies. <i>Cancer Biology and Medicine</i> , 2021, 18, 825-832.	3.0	0
7	Menopausal symptoms inversely associated with quality of life: findings from a 5-year longitudinal cohort in Chinese breast cancer survivors. <i>Menopause</i> , 2021, 28, 928-934.	2.0	2
8	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1375-1382.	2.6	20
9	The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1163-1175.	2.4	3
10	Dietary Pattern at 18-Month Post-Diagnosis and Outcomes of Breast Cancer Among Chinese Women with Early-Stage Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 4553-4565.	1.9	4
11	Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort. <i>BMC Cancer</i> , 2021, 21, 839.	2.6	2
12	Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials. <i>Oncologist</i> , 2021, 26, e2288-e2296.	3.7	6
13	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	3.6	7
14	Pre-diagnosis and early post-diagnosis dietary soy isoflavone intake and survival outcomes: A prospective cohort study of early stage breast cancer survivors. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100350.	1.7	5
15	Higher Level of Sports Activities Participation during Five-Year Survival Is Associated with Better Quality of Life among Chinese Breast Cancer Survivors. <i>Cancers</i> , 2021, 13, 6056.	3.7	5
16	Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study. <i>BMC Cancer</i> , 2020, 20, 1013.	2.6	6
17	Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine. <i>Data in Brief</i> , 2020, 30, 105421.	1.0	4
18	The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 167-180.	2.5	9

#	ARTICLE	IF	CITATIONS
19	Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer. <i>Breast Care</i> , 2020, 15, 655-666.	1.4	1
20	Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 24.	2.4	15
21	A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. <i>Breast</i> , 2020, 50, 30-38.	2.2	19
22	NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2019-002037.	1.6	5
23	Preservation of fertility in premenopausal patients with breast cancer. , 2020, 26, 216-226.		8
24	Changes in physical activity from pre-diagnosis to first five years post-diagnosis: A prospective cohort study in Chinese breast cancer patient.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24121-e24121.	1.6	1
25	Treating HR+/HER2 ⁻ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	2.5	29
26	Assessment of cancer health literacy among breast cancer patients in Hong Kong. <i>Breast</i> , 2019, 44, S129.	2.2	0
27	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. <i>IScience</i> , 2019, 21, 1-18.	4.1	12
28	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	3.7	180
29	Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. <i>Quality of Life Research</i> , 2019, 28, 2597-2607.	3.1	4
30	The association of liver function and quality of life of patients with liver cancer. <i>BMC Gastroenterology</i> , 2019, 19, 66.	2.0	21
31	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1298-1306.	6.3	83
32	<p>Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2719-2727.	1.9	8
33	A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541983650.	2.0	61
34	Abstract P1-12-07: Prospective 36-month follow-up to determine changes in body mass index and weight among Chinese breast cancer survivors. , 2019, , .		0
35	Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases. <i>Annals of Oncology</i> , 2019, 30, ix124-ix125.	1.2	0
36	Hypermethylation of NF- κ B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 676-686.	2.3	12

#	ARTICLE	IF	CITATIONS
37	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. <i>Radiology</i> , 2018, 287, 340-348.	7.3	4
38	Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 275-285.	4.9	29
39	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018, 118, 248-257.	6.4	71
40	Changes in body weight over 18-months follow-up among Chinese patients after breast cancer diagnosis. <i>Annals of Oncology</i> , 2018, 29, viii81-viii82.	1.2	1
41	Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer. <i>Annals of Oncology</i> , 2018, 29, ix2-ix3.	1.2	0
42	Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study. <i>Cancer Management and Research</i> , 2018, Volume 10, 4073-4084.	1.9	29
43	Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study. <i>Journal of Hepatology</i> , 2018, 68, S16.	3.7	11
44	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	7.0	63
45	Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 383-389.	1.9	10
46	Bone health in premenopausal Chinese patients after adjuvant chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , 2018, 92, S51.	2.8	0
47	Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study. <i>BMC Cancer</i> , 2018, 18, 162.	2.6	19
48	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. <i>Journal of Clinical Oncology</i> , 2018, 36, 475-475.	1.6	39
49	Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Hong Kong Medical Journal</i> , 2018, 24, 56-62.	0.1	3
50	Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 221-228.	2.8	47
51	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017, 116, 441-447.	6.4	46
52	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , 2017, 17, 8.	2.6	38
53	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	6.4	66
54	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	13.7	3,224

#	ARTICLE	IF	CITATIONS
55	Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study. <i>Journal of Hepatology</i> , 2017, 66, S34-S35.	3.7	6
56	Quality of life of premenopausal Chinese breast cancer patients after adjuvant chemotherapy. <i>Breast</i> , 2017, 32, S28.	2.2	0
57	Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study. <i>Journal of Hepatology</i> , 2017, 66, S620-S621.	3.7	1
58	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3977-3985.	4.1	22
59	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 280-289.	3.9	38
60	Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma. <i>Annals of Oncology</i> , 2017, 28, x116.	1.2	0
61	Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study. <i>Annals of Oncology</i> , 2017, 28, x57-x58.	1.2	3
62	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017, 49, 851-868.	3.0	50
63	Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. <i>BMC Women's Health</i> , 2017, 17, 55.	2.0	22
64	Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 Study. <i>Annals of Oncology</i> , 2017, 28, ix87.	1.2	0
65	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4013-4013.	1.6	76
66	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-226.	1.6	19
67	Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors. <i>Hong Kong Medical Journal</i> , 2017, 23, 54-62.	0.1	5
68	Value of quality of life analysis in liver cancer: A clinician's perspective. <i>World Journal of Hepatology</i> , 2017, 9, 867.	2.0	31
69	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15679-e15679.	1.6	0
70	Dyslipidaemias after adjuvant chemotherapy in young Chinese breast cancer patients. <i>Annals of Oncology</i> , 2016, 27, vi60.	1.2	0
71	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
72	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	4.4	217

#	ARTICLE	IF	CITATIONS
73	Goal adjustment influence on psychological well-being following advanced breast cancer diagnosis. <i>Psycho-Oncology</i> , 2016, 25, 58-65.	2.3	24
74	Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1766-1772.	2.8	47
75	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1300-1306.	2.8	103
76	Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 639-649.	0.5	6
77	Profile of mood states and quality of life of Chinese postmastectomy women in Hong Kong: Integrating variable- and person-centered approaches. <i>Health Care for Women International</i> , 2016, 37, 906-921.	1.1	3
78	State of the Art Antiemetic Therapy for Cancer Patients. <i>Current Oncology Reports</i> , 2016, 18, 2.	4.0	10
79	Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4012-4012.	1.6	23
80	2244 Integration of Albumin-Bilirubin (ALBI) score into current tumour staging system for hepatocellular carcinoma (HCC). <i>European Journal of Cancer</i> , 2015, 51, S414.	2.8	0
81	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1529-1535.	2.8	14
82	Prognostic Implication of Human Papillomavirus Types and Species in Cervical Cancer Patients Undergoing Primary Treatment. <i>PLoS ONE</i> , 2015, 10, e0122557.	2.5	18
83	Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles. <i>PLoS ONE</i> , 2015, 10, e0140842.	2.5	25
84	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
85	Phase I/II study of tlemsirrolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	2.6	96
86	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). <i>Liver Cancer</i> , 2015, 4, 96-105.	7.7	19
87	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-558.	1.6	1,810
88	P088 Early menopause and comorbidities among Chinese breast cancer women after adjuvant chemotherapy. <i>Breast</i> , 2015, 24, S55.	2.2	0
89	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 973-983.	3.4	9
90	Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA101-LBA101.	1.6	100

#	ARTICLE	IF	CITATIONS
91	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. Journal of Clinical Oncology, 2015, 33, 4073-4073.	1.6	0
92	Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. OncoTargets and Therapy, 2014, 7, 575.	2.0	45
93	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 439-450.	7.7	21
94	Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization. Radiology, 2014, 270, 607-620.	7.3	44
95	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 5976-5985.	7.0	95
96	Performance of serum α -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. Hpb, 2014, 16, 366-372.	0.3	48
97	O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENING. Journal of Hepatology, 2014, 60, S45-S46.	3.7	8
98	The evolution of supportive care needs trajectories in women with advanced breast cancer during the 12 months following diagnosis. Supportive Care in Cancer, 2014, 22, 635-644.	2.2	37
99	623: Efficacy of temsirolimus for advanced hepatocellular carcinoma (HCC) - assessment of pS6 as potential prognostic biomarker of response. European Journal of Cancer, 2014, 50, S148.	2.8	0
100	Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. Journal of Clinical Oncology, 2014, 32, 4094-4094.	1.6	3
101	Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World Journal of Gastroenterology, 2014, 20, 3135.	3.3	13
102	Risk factors and natural history of breast cancer in younger Chinese women. World Journal of Clinical Oncology, 2014, 5, 1097.	2.3	15
103	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chinese Journal of Cancer, 2014, 33, 481-91.	4.9	22
104	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. Journal of Clinical Oncology, 2014, 32, 181-181.	1.6	0
105	Supportive care needs in Hong Kong Chinese women confronting advanced breast cancer. Psycho-Oncology, 2013, 22, 1144-1151.	2.3	72
106	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 1417-1425.	2.3	12
107	Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 419-427.	2.5	35
108	Hepatitis B virus reactivation associated with anti-neoplastic therapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 31-37.	2.8	57

#	ARTICLE	IF	CITATIONS
109	Histone Deacetylase (HDAC) Inhibition in Hepatocellular Cancer. <i>Annals of Oncology</i> , 2013, 24, i7.	1.2	0
110	Prophylactic Use of Levonorgestrel-Releasing Intrauterine System in Women With Breast Cancer Treated With Tamoxifen. <i>Obstetrics and Gynecology</i> , 2013, 121, 943-950.	2.4	33
111	RE: Roles Played by Chemolipiodolization and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 580-580.	6.3	0
112	Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 2-5.	1.1	4
113	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	1.1	20
114	The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study. <i>Psycho-Oncology</i> , 2013, 22, 2831-2839.	2.3	75
115	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e54522.	2.5	46
116	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	1.6	167
117	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 3984-3992.	4.1	53
118	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16
119	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012, 83, 1146-1158.	4.4	28
120	Targeted therapy of hepatocellular carcinoma: Present and future. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 862-872.	2.8	72
121	A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4103-4103.	1.6	6
122	Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).. <i>Journal of Clinical Oncology</i> , 2012, 30, 259-259.	1.6	1
123	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0
124	A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14528-e14528.	1.6	0
125	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, 556-558.	3.7	40
126	6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma - a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). <i>European Journal of Cancer</i> , 2011, 47, S470-S471.	2.8	3

#	ARTICLE	IF	CITATIONS
127	Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2011, 38, 721-31.	3.3	22
128	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. <i>Future Oncology</i> , 2011, 7, 1149-1167.	2.4	191
129	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. <i>Breast Cancer: Targets and Therapy</i> , 2011, 3, 151.	1.8	15
130	Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1030-1038.	1.1	77
131	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 340-347.	2.8	75
132	P282 The menopausal status of young Chinese women with early stage breast cancer after adjuvant chemotherapy. <i>Breast</i> , 2011, 20, S68.	2.2	0
133	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , 2011, 19, 1625-1635.	2.2	42
134	Validation of the Chinese version of the Short-Form Supportive Care Needs Survey Questionnaire (SCNS-34). <i>Psycho-Oncology</i> , 2011, 20, 1292-1300.	2.3	68
135	Cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. <i>Journal of Medical Virology</i> , 2011, 83, 1023-1030.	5.0	8
136	The Epigenetic Modifier PRDM5 Functions as a Tumor Suppressor through Modulating WNT/ β -Catenin Signaling and Is Frequently Silenced in Multiple Tumors. <i>PLoS ONE</i> , 2011, 6, e27346.	2.5	64
137	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 205-205.	1.6	1
138	Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4058-4058.	1.6	0
139	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 107-114.	2.6	56
140	Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 620.	2.6	4
141	A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2409-2414.	2.3	8
142	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. <i>Liver International</i> , 2010, 30, 1427-1438.	3.9	35
143	T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer. <i>Vaccine Journal</i> , 2010, 17, 1315-1321.	3.1	7
144	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424

#	ARTICLE	IF	CITATIONS
145	421 The expression of CYP1B1 predicts neutropenia after adjuvant chemotherapy in breast cancer patients. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 179.	2.2	0
146	Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials. <i>Contemporary Clinical Trials</i> , 2010, 31, 135.	1.8	1
147	The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4028-4028.	1.6	0
148	Reply to L.T. Chen et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e272-e272.	1.6	1
149	New Utility of an Old Marker: Serial α -Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 446-452.	1.6	241
150	Reply to Y.X. Koo et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2571-2572.	1.6	4
151	0150 The severity of chemotherapy-induced neutropenia in association with PTGS-2 gene polymorphism in breast cancer patients. <i>Breast</i> , 2009, 18, S57.	2.2	0
152	TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. <i>International Journal of Cancer</i> , 2009, 124, 644-652.	5.1	192
153	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 529-535.	2.5	74
154	Hepatitis B virus reactivation in association with antineoplastic therapy. <i>Current Hepatitis Reports</i> , 2009, 8, 127-133.	0.3	0
155	Lymphedema and quality of life in Chinese women after treatment for breast cancer. <i>European Journal of Oncology Nursing</i> , 2009, 13, 110-115.	2.1	42
156	Role of α -fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , 2009, 5, 889-899.	2.4	30
157	Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 605-611.	1.6	576
158	Embolization Efficacy and Treatment Effectiveness of Transarterial Therapy for Unresectable Hepatocellular Carcinoma: A Case-Controlled Comparison of Transarterial Ethanol Ablation with Lipiodol-Ethanol Mixture versus Transcatheter Arterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 352-359.	0.5	31
159	Does severity of underlying chronic liver disease (CLD) affect treatment outcome of hepatocellular carcinoma (HCC) patients undergoing systemic chemotherapy (CT)? <i>Journal of Clinical Oncology</i> , 2009, 27, e15513-e15513.	1.6	0
160	Predictors of treatment outcomes in early stage hepatocellular carcinoma (HCC) detected in a surveillance program. <i>Journal of Clinical Oncology</i> , 2009, 27, 4584-4584.	1.6	0
161	A Comparison of Three Transarterial Lipiodol-Based Formulations for Hepatocellular Carcinoma: In Vivo Biodistribution Study in Humans. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 289-298.	2.0	8
162	Factors related to sexual health in Chinese women with breast cancer in Hong Kong. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 218-226.	1.1	10

#	ARTICLE	IF	CITATIONS
163	Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 25-33.	6.4	19
164	The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. <i>Journal of Hepatology</i> , 2008, 48, 433-441.	3.7	51
165	Transarterial Ethanol Ablation of Hepatocellular Carcinoma with Lipiodol-Ethanol Mixture: Phase II Study. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 95-103.	0.5	22
166	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
167	Predictors of Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection in Hong Kong. <i>Nursing Research</i> , 2008, 57, 416-425.	1.7	62
168	Quality of life (QOL) for breast cancer patients receiving aprepitant versus placebo for prevention of chemotherapy induced nausea and vomiting. <i>Journal of Clinical Oncology</i> , 2008, 26, 20549-20549.	1.6	21
169	Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- Prospective validation of the Chinese University Prognostic Index. <i>Journal of Clinical Oncology</i> , 2008, 26, 4591-4591.	1.6	1
170	Serial alpha-feto protein in predicting radiological response and overall survival of patient with inoperable hepatocellular carcinoma (HCC) during chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 4602-4602.	1.6	0
171	Sequential Chemotherapy with Combination Irinotecan and Cisplatin Followed by Docetaxel for Treatment-Naïve Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 838-844.	1.1	3
172	A Simple and Sensitive High-Performance Liquid Chromatographic Method for Quantification of PXD101, a Histone Deacetylase Inhibitor in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 231-235.	2.0	3
173	A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. <i>Annals of Oncology</i> , 2007, 18, 768-774.	1.2	84
174	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , 2007, 45, 1382-1389.	7.3	60
175	Should impaired liver function be held responsible for cognitive impairment and poor health-related quality of life in alcoholic cirrhosis?. <i>Hepatology</i> , 2007, 46, 950-950.	7.3	3
176	Reply:. <i>Hepatology</i> , 2007, 46, 1666-1666.	7.3	0
177	Adjuvant Chemoradiation for Gastric Cancer: Experience in the Chinese Population. <i>Clinical Oncology</i> , 2007, 19, 333-340.	1.4	10
178	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. <i>Oncogene</i> , 2007, 26, 7490-7498.	5.9	106
179	A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 1510-1515.	2.3	58
180	Irfolven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 295-300.	2.3	15

#	ARTICLE	IF	CITATIONS
181	Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. <i>Hepatology</i> , 2006, 43, 209-220.	7.3	474
182	Effects of Patupilone (Epothilone B; EPO906), a Novel Chemotherapeutic Agent, in Hepatocellular Carcinoma: An in vitro Study. <i>Oncology</i> , 2006, 71, 292-296.	1.9	22
183	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , 2006, 17, 1083-1089.	1.2	99
184	Correlation of Ki67, topo IIa, MRP1, p53 and p-gp with chemo-responsiveness and survival in patients with hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2006, 24, 4139-4139.	1.6	0
185	Prevention of Hepatitis B Virus Reactivation in Patients With Nasopharyngeal Carcinoma With Lamivudine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 379-384.	1.3	59
186	Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , 2005, 22, 303-312.	2.5	53
187	High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 266-272.	3.9	97
188	Knowledge, Perceptions, and Attitudes of Hong Kong Chinese Women on Screening Mammography and Early Breast Cancer Management. <i>Breast Journal</i> , 2005, 11, 52-56.	1.0	58
189	Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 536-539.	6.3	449
190	Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. <i>Acta Oncologica</i> , 2005, 44, 177-179.	1.8	2
191	Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2005, 68, 485-492.	1.9	15
192	An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 8041-8047.	1.6	36
193	A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α -2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1532-1538.	6.3	567
194	High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumorous tissue of breast cancer. <i>Pathology</i> , 2005, 37, 125-130.	0.6	31
195	Quality of life as a predicting factor for survival in 235 patients with inoperable hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2005, 23, 4125-4125.	1.6	0
196	A double-blind placebo-control randomized study of the efficacy of Chinese herbal medicine (CHM) in reduction of cytotoxic chemotherapy-induced toxicity. <i>Journal of Clinical Oncology</i> , 2005, 23, 8157-8157.	1.6	0
197	False-Negative Rate of Abdominal Sonography for Detecting Hepatocellular Carcinoma in Patients with Hepatitis B and Elevated Serum α -Fetoprotein Levels. <i>American Journal of Roentgenology</i> , 2004, 183, 453-458.	2.2	13
198	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , 2004, 15, 1661-1666.	1.2	153

#	ARTICLE	IF	CITATIONS
199	Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA. <i>Journal of Clinical Oncology</i> , 2004, 22, 3053-3060.	1.6	125
200	Brain Metastasis Responding to Gefitinib Alone. <i>Oncology</i> , 2004, 67, 174-178.	1.9	34
201	A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. <i>Acta Oncologica</i> , 2004, 43, 245-251.	1.8	7
202	Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 927-934.	1.6	255
203	Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. <i>British Journal of Cancer</i> , 2004, 90, 1306-1311.	6.4	290
204	Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 63-66.	1.0	53
205	Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2004, 88, 209-215.	2.5	88
206	Psychosocial impact of breast cancer surgeries in chinese patients and their spouses. <i>Psycho-Oncology</i> , 2004, 13, 132-139.	2.3	48
207	High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. <i>Journal of Viral Hepatitis</i> , 2004, 11, 55-59.	2.0	88
208	Application of expression genomics in drug development and genomic medicine. <i>Drug Development Research</i> , 2004, 62, 124-133.	2.9	4
209	Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. <i>Journal of Medical Virology</i> , 2003, 70, 553-561.	5.0	192
210	Unusual Abdominal Tumors. <i>Journal of Clinical Oncology</i> , 2003, 21, 955-956.	1.6	5
211	Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. <i>Clinical Cancer Research</i> , 2003, 9, 3376-82.	7.0	49
212	Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 2038-2044.	1.6	443
213	Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2002, 13, 655-662.	1.4	10
214	Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western series. <i>Radiotherapy and Oncology</i> , 2002, 62, 185-189.	0.6	49
215	Chemotherapy Induced Complete Remission in Malignant Phyllodes Tumor of the Prostate Metastasizing to the Lung. <i>Journal of Urology</i> , 2002, 168, 1104-1105.	0.4	24
216	Quality of Life of Palliative Care Patients in the Last Two Weeks of Life. <i>Journal of Pain and Symptom Management</i> , 2002, 24, 388-397.	1.2	54

#	ARTICLE	IF	CITATIONS
217	Frequent detection of the replicative form of TT virus DNA in peripheral blood mononuclear cells and bone marrow cells in cancer patients. <i>Journal of Medical Virology</i> , 2002, 66, 428-434.	5.0	57
218	A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.1	26
219	Immediate toxicity among Chinese patients undergoing adjuvant doxorubicin and cyclophosphamide for early breast cancer- a single institute experience with comparison to historic Western series. <i>European Journal of Cancer</i> , 2002, 38, S132.	2.8	0
220	Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. <i>Clinical Cancer Research</i> , 2002, 8, 1087-92.	7.0	138
221	Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung. <i>Journal of Urology</i> , 2002, 168, 1104-5.	0.4	13
222	Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. <i>Cancer Letters</i> , 2001, 162, 65-73.	7.2	43
223	Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. <i>Cancer Letters</i> , 2001, 167, 183-191.	7.2	41
224	Hepatocellular carcinoma and lymphoma "two hepatitis B virus related malignant diseases?". <i>Lancet Oncology</i> , The, 2001, 2, 543.	10.7	3
225	Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. <i>Clinica Chimica Acta</i> , 2001, 313, 179-185.	1.1	20
226	The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong. <i>Pharmacoeconomics</i> , 2001, 19, 947-953.	3.3	25
227	Quantitative and genotypic analysis of TT virus infection in Chinese blood donors. <i>Transfusion</i> , 2001, 41, 1001-1007.	1.6	17
228	Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. <i>Journal of Medical Virology</i> , 2001, 65, 473-477.	5.0	56
229	Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 2369-2377.	4.1	24
230	High Carriage Rate of TT Virus in the Cervices of Pregnant Women. <i>Clinical Infectious Diseases</i> , 2001, 32, 1376-1377.	5.8	27
231	Quantitative correlation of cytokeratin 19 mRNA level in peripheral blood with disease stage and metastasis in breast cancer patients: potential prognostic implications. <i>International Journal of Oncology</i> , 2001, 18, 633-8.	3.3	6
232	Cross-cultural validation of the McGill Quality of Life questionnaire in Hong Kong Chinese. <i>Palliative Medicine</i> , 2001, 15, 387-397.	3.1	70
233	Gross Elevation of TT Virus Genome Load in the Peripheral Blood Mononuclear Cells of Cancer Patients. <i>Annals of the New York Academy of Sciences</i> , 2001, 945, 84-92.	3.8	37
234	Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. <i>Journal of Medical Virology</i> , 2001, 65, 473-477.	5.0	2

#	ARTICLE	IF	CITATIONS
235	Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. <i>Journal of Medical Virology</i> , 2000, 60, 249-255.	5.0	84
236	Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. <i>Journal of Medical Virology</i> , 2000, 62, 299-307.	5.0	604
237	Sonographic findings in masseter-muscle metastases. <i>Journal of Clinical Ultrasound</i> , 2000, 28, 299-302.	0.8	12
238	A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2000, 89, 543-550.	4.1	18
239	Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. <i>Journal of Viral Hepatitis</i> , 2000, 7, 448-458.	2.0	36
240	Hemorrhagic Pyelitis, Ureteritis, and Cystitis Secondary to Cyclophosphamide: Case Report and Review of the Literature. <i>Gynecologic Oncology</i> , 2000, 76, 223-225.	1.4	28
241	Longitudinal Colour Doppler Study of Superficial Lymph Nodes in Non-Hodgkin's Lymphoma Patients on Chemotherapy. <i>Clinical Radiology</i> , 2000, 55, 110-113.	1.1	15
242	TT virus: a study of molecular epidemiology and transmission of genotypes 1, 2 and 3. <i>Journal of Clinical Virology</i> , 2000, 17, 43-49.	3.1	53
243	Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs. <i>American Journal of Clinical Dermatology</i> , 2000, 1, 113-116.	6.7	44
244	Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer. <i>Radiotherapy and Oncology</i> , 2000, 54, 201-208.	0.6	6
245	Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. <i>Journal of Medical Virology</i> , 2000, 60, 249.	5.0	10
246	Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. , 2000, 62, 299.		1
247	Prevalence of Mutations in the BRCA1 Gene Among Chinese Patients With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 882-885.	6.3	59
248	Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. <i>Journal of Viral Hepatitis</i> , 1999, 6, 195-202.	2.0	42
249	Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 124-130.	2.3	22
250	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 307-311.	2.3	50
251	Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. , 1999, 59, 263-269.		84
252	Quantitative analysis of circulating tumour cells in breast cancer patients using reverse transcriptase polymerase chain reaction. <i>European Journal of Cancer</i> , 1999, 35, S90.	2.8	0

#	ARTICLE	IF	CITATIONS
253	A phase II study of gemcitabine plus oral etoposide (GOE) in treatment of advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 1999, 35, S255.	2.8	0
254	Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial. <i>Lancet, The</i> , 1999, 353, 797-801.	13.7	436
255	Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. , 1998, 82, 2439-2448.		19
256	Desmoid tumor mimicking local recurrence of carcinoma of the breast. <i>International Journal of Clinical Oncology</i> , 1998, 3, 49-51.	2.2	2
257	Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 247-249.	2.3	12
258	A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 1998, 34, 2027-2031.	2.8	101
259	Injection sclerotherapy for variceal bleeding in patients with hepatocellular carcinoma: cyanoacrylate versus sodium tetradecyl sulphate. <i>Gastrointestinal Endoscopy</i> , 1998, 47, 235-239.	1.0	42
260	Case two. Bleomycin cutaneous toxicity.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1626-1627.	1.6	0
261	Transdermal fentanyl for severe cancer-related pain. <i>Palliative Medicine</i> , 1997, 11, 233-239.	3.1	22
262	Radiation-recall dermatitis with docetaxel: Establishment of a requisite radiation threshold. <i>European Journal of Cancer</i> , 1997, 33, 698-699.	2.8	82
263	MRI and CT of metastatic hepatocellular carcinoma causing spinal cord compression. <i>Clinical Radiology</i> , 1997, 52, 755-760.	1.1	23
264	Carbamazepine-induced lymphadenopathy mimicking Ki-1 (CD30 +) T-cell lymphoma. <i>Pathology</i> , 1997, 29, 64-66.	0.6	11
265	COSMETIC OUTCOME OF BREAST-CONSERVING THERAPY IN CHINESE PATIENTS WITH EARLY BREAST CANCER. <i>ANZ Journal of Surgery</i> , 1997, 67, 771-774.	0.7	8
266	Nasal lymphoma: Results of local radiotherapy with or without chemotherapy. , 1997, 19, 251-259.		22
267	Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 466-470.	2.3	54
268	Hepatic angiomyelolipoma and tuberous sclerosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 196-198.	2.8	8
269	Rapid healing of an indolent leg ulcer with topical rhGM-CSF. <i>Australian and New Zealand Journal of Medicine</i> , 1996, 26, 420-421.	0.5	11
270	Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma-frequency of specific banding patterns at non-diagnostic serum levels. <i>British Journal of Cancer</i> , 1996, 73, 985-988.	6.4	18

#	ARTICLE	IF	CITATIONS
271	Small cell variant of Ki-1 lymphoma associated with myelofibrosis and a novel constitutional chromosomal translocation t(3;4) (q13;q12).. Journal of Clinical Pathology, 1996, 49, 259-262.	2.0	3
272	A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 1995, 33, 569-577.	0.8	270
273	A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma. Digestive Diseases and Sciences, 1995, 40, 2516-2521.	2.3	40
274	Treatment Horizons for Triple-negative Breast Cancer. Hong Kong Journal of Radiology, 0, , 111-118.	0.1	2